Erratum: ‘Corrigendum to “2017 Taiwan lipid guidelines for high risk patients” [Journal of the Formosan Medical Association (2017) [217–248]’(S0929664616304302)(10.1016/j.jfma.2016.11.013)

The Writing Group of 2017 Taiwan Lipid Guidelines for High Risk Patients

研究成果: Comment/debate同行評審

摘要

In the page 225, left column, lines 3–7 of the article cited above, the sentence “The European Medicines Agency has approved alirocumab and evolocumab for patients who fail to achieve acceptable lipid control despite optimal statin therapy, patients with homozygous FH (HoFH), and statin-intolerant patients”, should have read “The European Medicines Agency has approved alirocumab and evolocumab for patients who fail to achieve acceptable lipid control despite optimal statin therapy, patients with homozygous FH (HoFH; evolocumab only), heterozygous FH, and statin-intolerant patients.” The authors would like to apologize for any inconvenience caused.

原文English
頁(從 - 到)749-750
頁數2
期刊Journal of the Formosan Medical Association
117
發行號8
DOIs
出版狀態Published - 2018 八月

All Science Journal Classification (ASJC) codes

  • Medicine(all)

指紋 深入研究「Erratum: ‘Corrigendum to “2017 Taiwan lipid guidelines for high risk patients” [Journal of the Formosan Medical Association (2017) [217–248]’(S0929664616304302)(10.1016/j.jfma.2016.11.013)」主題。共同形成了獨特的指紋。

引用此